- Home
- WCT vs QNTM Comparison
WCT vs QNTM Comparison
Compare WCT & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- QNTM
- Stock Information
- Founded
- WCT 2012
- QNTM 1998
- Country
- WCT Hong Kong
- QNTM Canada
- Employees
- WCT N/A
- QNTM N/A
- Industry
- WCT
- QNTM
- Sector
- WCT
- QNTM
- Exchange
- WCT NYSE
- QNTM NYSE
- Market Cap
- WCT 9.7M
- QNTM 69.3M
- IPO Year
- WCT 2024
- QNTM N/A
- Fundamental
- Price
- WCT $0.22
- QNTM $18.56
- Analyst Decision
- WCT
- QNTM
- Analyst Count
- WCT 0
- QNTM 0
- Target Price
- WCT N/A
- QNTM N/A
- AVG Volume (30 Days)
- WCT 550.3K
- QNTM 408.2K
- Earning Date
- WCT 05-16-2025
- QNTM 08-13-2025
- Dividend Yield
- WCT N/A
- QNTM N/A
- EPS Growth
- WCT N/A
- QNTM N/A
- EPS
- WCT N/A
- QNTM N/A
- Revenue
- WCT $2,309,218.00
- QNTM N/A
- Revenue This Year
- WCT N/A
- QNTM N/A
- Revenue Next Year
- WCT N/A
- QNTM N/A
- P/E Ratio
- WCT N/A
- QNTM N/A
- Revenue Growth
- WCT N/A
- QNTM N/A
- 52 Week Low
- WCT $0.12
- QNTM $2.70
- 52 Week High
- WCT $9.36
- QNTM $38.25
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- QNTM 50.64
- Support Level
- WCT N/A
- QNTM $15.88
- Resistance Level
- WCT N/A
- QNTM $24.32
- Average True Range (ATR)
- WCT 0.00
- QNTM 3.58
- MACD
- WCT 0.00
- QNTM -1.07
- Stochastic Oscillator
- WCT 0.00
- QNTM 13.59
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.